Many drugs, or their antecedents, were discovered through observation of their effects on
normal or disease physiology. For the past generation, this phenotypic drug discovery …

Chronic hepatitis B virus (HBV) infection is a common cause of liver disease globally, with a
disproportionately high burden in South-East Asia. Vaccines and nucleoside or nucleotide …

Hepatitis B virus (HBV) specifically infects hepatocytes and causes severe liver diseases.
The HBV life cycle is unique in that the genomic DNA (relaxed-circular partially double …

Representatives from academia, industry, regulatory agencies, and patient groups
convened in March 2019 with the primary goal of developing agreement on chronic hepatitis …

Antiviral drugs have traditionally been developed by directly targeting essential viral
components. However, this strategy often fails due to the rapid generation of drug-resistant …

Wilson disease (WD) is an inherited disorder of hepatic copper metabolism with
considerable variation in clinical presentations, the most common ones being liver disease …

RNA tailing, or the addition of non-templated nucleotides to the 3′ end of RNA, is the most
frequent and conserved type of RNA modification. The addition of tails and their composition …

The number of sequenced viral genomes has surged recently, presenting an opportunity to
understand viral diversity and uncover unknown regulatory mechanisms. Here, we …

Background & Aims The persistence of covalently closed circular DNA (cccDNA) in infected
hepatocytes is the major barrier preventing viral eradication with existing therapies in …

Hepatitis B virus (HBV) infection affects approximately 300 million people worldwide.
Although antiviral therapies have improved the long-term outcomes, patients often require …